Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
28.41
-0.76 (-2.61%)
Nov 2, 2026, 4:00 PM EST - Market closed
Immunovant Market Cap
Immunovant has a market cap or net worth of $5.87 billion as of November 2, 2026. It is the 3,097th most valuable company in the world and the 1,024th biggest in the United States. Its market cap has increased by 36.40% in one year.
Market Cap
5.87B
Enterprise Value
5.07B
1-Year Change
36.40%
Global Rank
Country Rank
#1,024 United States
Category
ChartMarket Cap Chart
Since June 21, 2019, Immunovant's market cap has increased from $124.38M to $5.87B, an increase of 4,618.12%. That is a compound annual growth rate of 68.67%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 2, 2026 | 5.87B | 13.90% |
| Dec 31, 2025 | 5.15B | 41.70% |
| Dec 31, 2024 | 3.64B | -40.34% |
| Dec 29, 2023 | 6.09B | 165.79% |
| Dec 30, 2022 | 2.29B | 134.03% |
| Dec 31, 2021 | 979.80M | -78.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 21, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Ionis Pharmaceuticals | 7.23B |
| Ligand Pharmaceuticals | 6.43B |
| Oruka Therapeutics | 6.41B |
| Rhythm Pharmaceuticals | 6.37B |
| Belite Bio | 6.23B |
| Kodiak Sciences | 6.22B |
| Veradermics | 5.84B |
| CG Oncology | 5.73B |